


Max India Limited

Investor Release

25 January 2022







Safe Harbour

This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Max India Limited** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.








1	Consolidated Revenue grows 98% to Rs 186 Cr, and EBITDA turns positive to Rs 1.4 Cr in 9MFY22 vs loss of Rs 22.5 Cr in PY , primarily due to higher sales collection and lower finance cost in Doon
2	Capital reduction update: Scheme has been filed with NCLT in Sep 21, final hearing is in Feb'22 and closing expected in Q4FY22. Max India has sufficient Treasury Corpus of Rs 378 Cr to support Capital reduction (Rs 92 Cr) and Antara's growth
3	Dehradun : Cumulative units sold at 169 and Sales collections at Rs 486 Cr as of Dec'21. Achieved monthly sales velocity of 4 units and monthly sales collection of Rs 12 Cr in Q3FY22. Debt reduced to Rs 18 Cr as of Dec'21 Noida: Cumulative units sold at 213 and Sales collections at Rs 66 Cr as of Dec'21; Construction work started for Phase 1
4	Care at Home: Net revenue at Rs 7.5 Cr and Contribution margin at 21% in 9MFY22 vs 12% in FY21. Q3FY22 revenue at Rs 1.28 Cr, grew 27% y-o-y
5	Care Homes : Net revenue at Rs 3.2 Cr in 9MFY22; Contribution margin improved to -32% in 9MFY22 vs -227% in FY21; Q3FY22 revenue at Rs 1 Cr, grew 256% y-o-y
6	MedCare: Net revenue clocked at Rs 2.9 Cr and Contribution margin at 5% in 9MFY22. Q3FY22 revenue at Rs 0.7 Cr, grew 203% y-o-y and 37% q-o-q


Residences for Seniors

Antara Dehradun – Achieved monthly sales velocity of 4 units and monthly sales collection of Rs 12 Cr in Q3FY22. Debt reduced to Rs 18 Cr





Cumulative sales and collection trend






* for last 3 months

A Max Group Company

Antara Noida – Achieved monthly sales velocity of 6 units and monthly sales collection of Rs 5.3 Cr in Q3FY22





A Max Group Company

Care at Home

Care at Homes – Q3FY22 Revenues increased by 27% YoY led by better realisations

Revenues from Care at Home segment increased sharply during Q1FY21 driven by higher contribution from COVID services





9MFY22 Contribution from Care at Home 21% (Rs 154 lacs), driven by COVID led services revenue

Outlook

Increase the market coverage and achieve scale

Deepening the offerings basket and focusing on creating differentiated products

Increasing service delivery capacity and building strong clinical capabilities




(a) Revenue reported above is on net basis after discounts
(b) Contribution is derived at by allocating all direct costs attributable to the respective business lines. [Contribution = (Gross revenue less discounts) – (Direct costs)]
(c) Volume served numbers reported above are on approximate basis



Care Homes/ Memory Care Homes

Care Homes/Memory Care Homes: Q3FY22 Revenues increased by 256% YoY led by significant improvement in Occupancy Ratio



9MFY22 Contribution from Care Homes -32% (- Rs 100 lacs)

- 1. Q3FY22 Revenue: Gurgaon Care Home Rs 0.61 Cr and GK Care Home at Rs 0.33 Cr
- 2. Q3FY22 occupancy for Gurgaon at 36% and GK at 14%

Occupancy trend at Care Homes (bed days)

3. Center break-even expected at ~45-50% occupancy

(a) Revenue reported above is on net basis after discounts
(b) Contribution is derived at by allocating all direct costs attributable to the respective business lines. [Contribution = (Gross revenue less discounts) – (Direct costs)]
(c) Occupied bed days numbers reported above are on approximate basis



Care Homes Revenue (Rs Lacs)

MedCare

6

The Party Name

MedCare: Q3FY22 Revenues increased by 203% YoY

MedCare Revenue (Rs Lacs) 200 MedCare 180 171.5 Products ANTARA 💪 A Max Group Company 160 140 A Portfolio of over 1K Products 120 **Pricing:** Transparent/ fair pricing (Antara Retail Price) 100 80 Better **product quality**/ features/ packaging 203% 65.4 YoY 60 47.8 47.3 Superior service/ sales support 40 21.6 20 6.8 0.9 0 Q3FY21 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q1FY21 Q2FY21

9MFY22 Contribution 5% (Rs 15 lacs), driven by COVID led products revenue



(a) Revenue reported above is on net basis after discounts

(b) Contribution is derived at by allocating all direct costs attributable to the respective business lines. [Contribution = (Gross revenue less discounts) – (Direct costs)]




Consolidated Financials

2200

AND IS SALAN

155

Robust liquidity of Rs 378 Cr and other monetizable assets of Rs 160 Cr as on Dec-21 $\,$



Antara 2.0 – Growth (Asset Light) Invested Capital (Rs 213 Cr)

Investment in Noida project; Greater Noida Land parcel and intangibles



Care Homes Care at Home MedCare Products

New Businesses (Rs 36 Cr) (Care at Home, Care Home and MedCare)

Care at Home (Home Care) – Launched in Q1FY21

Care Homes (Assisted Living) -

Gurgaon launched in Q2FY21 and Delhi launched in Q3FY21

MedCare – Launched in Q3FY21



Other Assets[^] (Rs 478 Cr)

Cash & cash equivalents[^] – Rs 378 Cr

Antara Growth Capital – Rs 265 Cr.

(to be deployed over next 3-4 years)

- Assisted Care Services Rs. 190 Cr.
- Residences for Seniors Rs. 75 Cr.

Surplus Capital – Rs 21 Cr.

Capital reduction – Rs 92 Cr. (1.08 Cr shares at Rs 85 per share)

Other monetisable asset – Rs 100 Cr

Max Towers (61k sq ft) – Rs 100 Cr

^As on 31^{st} Dec'21 end includes unrealized gain on MF/ FD of Rs 14 Cr





Particulars (Rs. Crs.)	Q3 FY22	Q3 FY21	Ү-о-Ү	9M FY22	9M FY21	Y-o-Y
Total Income	42.8	34.2	25%	186.0	93.8	98%
Total Expenses	43.6	38.6		184.6	116.3	
EBITDA	(0.7)	(4.4)	83%	1.4	(22.5)	>100%
Depreciation	2.2	2.6		6.7	7.8	
EBIT	(3.0)	(7.0)	58%	(5.3)	(30.2)	83%
Finance Cost	2.0	5.7		9.2	19.9	
Profit Before Tax	(4.9)	(12.7)	61%	(14.5)	(50.1)	71%
Тах	0.8	0.3		2.0	(6.5)	
Profit After Tax	(5.7)	(13.0)	56%	(16.5)	(43.6)	62%
EPS	(1.1)	(2.4)		(3.1)	(8.1)	



Balance Sheet: Strong BS position with Net worth of Rs 638 Cr

Particulars (Rs in Crs.)	31-Dec-21	31-Mar-21
Non-Current Assets	200.1	209.5
Current Assets	642.6	787.6
Total Assets	842.7	997.6



Company



Max India Limited CIN: L85100MH2015PLC330122 Mr. Ajay Agrawal ajay.agrawal@antaraseniorcare.com https://www.maxindia.com/

Investor Relations Advisors

$SGA \stackrel{Strategic \ Growth \ Advisors}{}$

Strategic Growth Advisors Pvt. Ltd. CIN: U74140MH2010PTC204285 Mr. Vijay Goel / Mr. Aakash Mehta vijay.goel@sgapl.net / Aakash.s.m@sgapl.net +91 9920124357 / +91 9870679263 www.sgapl.net



